Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +20.83%
#4 Bedrock Bedrock +18.46%
#5 Nockchain Nockchain +16.07%
#6 Velvet Velvet +14.00%
#7 Fabric Protocol Fabric Protocol +13.90%
#8 Perle Perle +12.76%
#9 Starpower Starpower +12.51%
#10 Nillion Nillion +12.50%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Idogen AB (publ) Idogen AB (publ)

Idogen AB (publ)

IDOGEN
Rank in Stocks #37811
Idogen AB (publ) is a Swedish biotechnology company specializing in the... Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Share Price
$0.01345907
Last synced: 2024-07-12
Market Cap
$1.43M
Change (1 day)
22.16%
Change (1 year)
0.00%
Country
SE
Trade Idogen AB (publ) (IDOGEN)

Category

Healthcare
P/E ratio for Idogen AB (publ) (IDOGEN)
P/E ratio as of 2026 TTM: 0
According to Idogen AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Idogen AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.